Lumos Pharma

AUSTIN, Texas, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials, announced it will report its full year 2023 financial results after market close on Thursday, March 7, 2024. The company will host a conference call and webcast at 4:30 PM ET that day to discuss these financial results and provide an update on clinical and corporate activities. A question-and-answer session will follow the prepared remarks. » Mehr auf globenewswire.com

Lumos Pharma (LUMO) came out with a quarterly loss of $1.04 per share versus the Zacks Consensus Estimate of a loss of $1.10. This compares to loss of $0.86 per share a year ago. » Mehr auf zacks.com

AUSTIN, Texas, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for moderate Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials, announced that the Company will participate in the H.C. Wainwright 25th Annual Global Investment Conference being held September 11th – 13th and the Cantor Global Healthcare Conference 2023 being held September 26th – 28th in New York City. Lumos Pharma management will present and host one-on-one meetings at both conferences. » Mehr auf globenewswire.com